Gilead Sciences Inc

NASDAQ:GILDUnited States

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases includes Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. It sells and distributes its products in the United States through the wholesale channel. It operates in more than 35 countries worldwide.

Contact Information

Headquarters

333 LAKESIDE DRFOSTER CITY, CA, United States 94404

Phone

650-574-3000

Fax

650-578-9264

Executives

Chairman of the Board, Chief Executive Officer

Daniel O'Day

Chief Financial Officer

Andrew Dickinson

Executive Vice President - Corporate Affairs, General Counsel, Corporate Secretary

Deborah Telman

Executive Vice President - Pharmaceutical Development and Manufacturing

Stacey Ma

Executive Vice President - Research

Flavius Martin